Tower Research Capital (TRC)’s Invesco Pharmaceuticals ETF PJP Stock Holding History

Tower Research Capital (TRC)’s Portfolio PJP Stock Details PJP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,825	Closed	-$189K	–	5539
2026 Q1	$189K	Buy	+1,825	New	+$193K	﹤0.01%	1666
2025 Q4	–	Sell	-15	Closed	-$1.39K	–	5481
2025 Q3	$1.39K	Sell	15 -4,665	-100%	-$408K	﹤0.01%	4801
2025 Q2	$374K	Buy	4,680 +2,374	+103%	+$189K	0.01%	1225
2025 Q1	$200K	Sell	2,306 -1,094	-32%	-$93.2K	0.01%	1376
2024 Q4	$281K	Sell	3,400 -3,641	-52%	-$313K	0.01%	1457
2024 Q3	$612K	Buy	7,041 +1,543	+28%	+$132K	0.02%	747
2024 Q2	$452K	Buy	5,498 +760	+16%	+$60.4K	0.01%	1431
2024 Q1	$380K	Buy	4,738 +4,707	+15,184%	+$365K	0.01%	1026
2023 Q4	$2.36K	Sell	31 -6,540	-100%	-$468K	﹤0.01%	5233
2023 Q3	$476K	Sell	6,571 -1,926	-23%	-$148K	0.01%	895
2023 Q2	$643K	Buy	8,497 +2,189	+35%	+$167K	0.02%	812
2023 Q1	$480K	Buy	6,308 +4,571	+263%	+$352K	0.02%	854
2022 Q4	$136K	Sell	1,737 -5,663	-77%	-$435K	0.01%	1587
2022 Q3	$527K	Buy	7,400 +5,825	+370%	+$434K	0.01%	1098
2022 Q2	$118K	Buy	1,575 +1,545	+5,150%	+$117K	﹤0.01%	2155
2022 Q1	$2K	Sell	30 -3,177	-99%	-$246K	﹤0.01%	5582
2021 Q4	$260K	Sell	3,207 -8,061	-72%	-$637K	﹤0.01%	1573
2021 Q3	$871K	Buy	11,268 +11,238	+37,460%	+$906K	0.02%	617
2021 Q2	$2K	Hold	30	–	–	﹤0.01%	5065
2021 Q1	$2K	Sell	30 -2,986	-99%	-$233K	﹤0.01%	5038
2020 Q4	$215K	Sell	3,016 -4,996	-62%	-$334K	0.01%	1647
2020 Q3	$512K	Sell	8,012 -3,664	-31%	-$239K	0.01%	1660
2020 Q2	$756K	Buy	11,676 +11,646	+38,820%	+$724K	0.03%	705
2020 Q1	$2K	Sell	30 -11,279	-100%	-$687K	﹤0.01%	2623
2019 Q4	$732K	Sell	11,309 -7,793	-41%	-$474K	0.06%	172
2019 Q3	$1.08M	Buy	19,102 +19,072	+63,573%	+$1.1M	0.07%	265
2019 Q2	$2K	Sell	30 -28,059	-100%	-$1.72M	﹤0.01%	3297
2019 Q1	$1.83M	Buy	28,089 +4,644	+20%	+$305K	0.11%	140
2018 Q4	$1.46M	Buy	23,445 +23,415	+78,050%	+$1.58M	0.11%	192
2018 Q3	$2K	Sell	30 -19,461	-100%	-$1.4M	﹤0.01%	3463
2018 Q2	$1.31M	Sell	19,491 -12,481	-39%	-$803K	0.07%	266
2018 Q1	$2M	Sell	31,972 -3,560	-10%	-$234K	0.17%	88
2017 Q4	$2.28M	Buy	35,532 +24,047	+209%	+$1.54M	0.29%	60
2017 Q3	$751K	Sell	11,485 -35,990	-76%	-$2.27M	0.06%	175
2017 Q2	$2.98M	Buy	47,475 +17,910	+61%	+$1.08M	0.34%	46
2017 Q1	$1.74M	Sell	29,565 -15,466	-34%	-$904K	0.17%	51
2016 Q4	$2.52M	Buy	45,031 +30,992	+221%	+$1.78M	0.27%	82
2016 Q3	$865K	Buy	14,039 +962	+7%	+$63K	0.09%	93
2016 Q2	$829K	Sell	13,077 -11,152	-46%	-$701K	0.08%	181
2016 Q1	$1.46M	Sell	24,229 -9,516	-28%	-$582K	0.22%	79
2015 Q4	$2.36M	Sell	33,745 -18,610	-36%	-$1.32M	0.38%	32
2015 Q3	$3.47M	Buy	52,355 +46,052	+731%	+$3.58M	0.34%	40
2015 Q2	$494K	Buy	+6,303	New	+$491K	0.04%	143
2014 Q2	–	Sell	-153,051	Closed	-$8.67M	–	4498
2014 Q1	$8.67M	Buy	+153,051	New	+$8.69M	1.11%	7

Other funds holding PJP

PAM

Peak Asset Management Louisville, Colorado $680M AUM 22.27% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

MML Investors Services Springfield, Massachusetts $49B AUM 25.55% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

JGCM

Joseph Group Capital Management Columbus, Ohio $476M AUM 21.21% 1-Year Est. Return

Tower Research Capital (TRC)'s PJP Position: Q2 2026 in Review

Tower Research Capital (TRC) sold out of Invesco Pharmaceuticals ETF (PJP) in Q2 2026, closing a stake of 1,825 shares — an estimated $189K sold.

Tower Research Capital (TRC) first reported a position in PJP in Q1 2014 and held it in 44 quarters. The position peaked at $8.67M in Q1 2014. 117 funds tracked by Wall St. Rank hold PJP as of Q2 2026.

Tower Research Capital (TRC) reported no remaining Invesco Pharmaceuticals ETF position as of Q2 2026 after selling out during the quarter.
Tower Research Capital (TRC) sold 1,825 Invesco Pharmaceuticals ETF shares in Q2 2026, an estimated $189K.
Tower Research Capital (TRC) first reported a position in Invesco Pharmaceuticals ETF in Q1 2014 and held it in 44 quarters.
Tower Research Capital (TRC)'s Invesco Pharmaceuticals ETF position peaked at $8.67M in Q1 2014.
117 funds tracked by Wall St. Rank held Invesco Pharmaceuticals ETF as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.